The price of Karelizumab is about 2928 yuan/200mg, which needs to be determined in conjunction with the health insurance policy.
Karelizumab belongs to the humanized PD-1 monoclonal antibody class of drugs, can be combined with the PD-1 receptor, thus blocking the pathway of PD-1, PD-L1, restoring the patient’s original tumor immunity, so as to remove the cancer cells from the body, and it can be used for the treatment of classic Hodgkin’s lymphoma, esophageal squamous carcinoma, advanced hepatocellular carcinoma, and non-squamous non-small cell lung cancer.
The current price of the drug is about 2,928 yuan / 200mg or so, but different regional health insurance policies, reimbursement rates are different, the specific cost of the aspect will have some differences.
Karelizumab during the use of medication will appear reactive capillary hyperplasia, aspartate aminotransferase elevation and other adverse reactions, the use of medication during the need to do a good job of related testing.
The drug should be used under the guidance of a doctor, do not blindly use drugs, so as not to delay treatment.